| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5655569 | Digestive and Liver Disease | 2017 | 7 Pages |
Abstract
Adalimumab dose escalation is an effective and well-tolerated therapeutic option in patients with secondary loss of response. A 40Â mg every week optimized regimen was predictive of a response to ADA dose escalation.
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Nicolas Duveau, Maria Nachury, Romain Gerard, Julien Branche, Vincent Maunoury, Medina Boualit, Pauline Wils, Pierre Desreumaux, Benjamin Pariente,